Original news and analysis on international IP policy
The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) announced the identification of three potential drug classes for the treatment of neglected tropical diseases through the availability of hundreds of compounds in the public domain.
Greg Perry, a longtime leader in the European generics industry, has been named the new executive director of the Medicines Patent Pool, a cutting-edge Geneva-based group working to increase access to affordable, high-quality medicines for HIV/AIDS patients in low and middle income countries.
In the recent decision on the case “Novartis AG versus Laboratorios LKM SA re cease of use of patent” the Third Chamber of the Federal Civil and Commercial Appellate Court of Argentina set an important precedent in relation to the interpretation of the ius prohibendi of patent holders. In other words, the demarcation of what they can and cannot prohibit.
A proposal of the European Patent Office President Benoît Battistelli to pay a collective reward to EPO staff in 2012 in view of the positive operating result of 2011 has stirred concerns about the kind of incentive this might give to EPO examiners.
The Global Fund against AIDS, Tuberculosis and Malaria, a health financing institution focused on the global South, is poised this week to select its next director – from the North. And while the selection process has been conducted in the utmost secrecy, confidential selection documents show that the list is down to four candidates, said to be from Canada, France, the United Kingdom, and the United States.
After a difficult session last May, the World Intellectual Property Organization committee examining the development dimension of WIPO activities will reconvene next week with a substantive agenda. In particular, delegates will assess progress of ongoing projects, consider reports on finished projects, and consider the committee's future work. They also will consider a conference on IP and development.
The industry practice of extending patent protection on pharmaceuticals by obtaining additional patents on other features of the drug ingredients can lead to decades of delay in generic competition, a new study argues.
World Health Organization members this week achieved consensus on a set of voluntary targets and indicators for the prevention and control of the world’s biggest killers including cancer, diabetes, cardiovascular and chronic respiratory diseases. Two targets and several indicators relate to national health systems response.
The European Union’s global plan for health, development cooperation includes the commitment that high-quality medicines and care in the developing world be available without restrictions. As such, despite its growing impact and strong investment in product R&D, the plan seemingly lacks adequate coherence, innovative financing, and coordination, collaboration with concerned parties. Filling these gaps would be a matter of priority and a way for the EU to achieve indisputable field leadership.
The only independent external oversight body of the United Nations has launched a new website, making it easier to access its reports dating back to 1968, and other information.
An outside meeting of experts has prepared a report ahead of this month’s gathering of World Health Organization members hoping to agree on new models for financing research and development for diseases lacking adequate market mechanisms and public policies. These include neglected diseases that predominantly affect poor populations unable to pay high prices needed to defray R&D costs under the existing commercial model.
The government of India has released a set of draft guidelines to be followed in the patenting of traditional knowledge and biological material. Comments are due by 22 November.